Cancer Chemotherapy Update - Dasatinib; Panitumumab

Moshe Talpaz, Neil P. Shah, Hagop Kantarjian, Nicholas Donato, John Nicoll, Ron Paquette, Jorge Cortes, Susan O'Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath Iyer, Tai-Tsang Chen, Fei Huang, Arthur P. Decillis, Charles L. Sawyers, Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias The New England Journal of Medicine. ,vol. 354, pp. 2531- 2541 ,(2006) , 10.1056/NEJMOA055229

Eric K. Rowinsky, Garry H. Schwartz, Jared A. Gollob, John A. Thompson, Nicholas J. Vogelzang, Robert Figlin, Ronald Bukowski, Naomi Haas, Pamela Lockbaum, Yu-Ping Li, Rosalin Arends, Kenneth A. Foon, Gisela Schwab, Janice Dutcher, Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3003- 3015 ,(2004) , 10.1200/JCO.2004.11.061

I. Malik, J. R. Hecht, A. Patnaik, A. Venook, J. Berlin, G. Croghan, L. Navale, M. MacDonald, S. Jerian, N. J. Meropol, Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology. ,vol. 23, pp. 3520- 3520 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3520

L. M. Weiner, A. Belldegrun, E. Rowinsky, J. Crawford, P. Lockbaum, S. Huang, R. Arends, G. Schwab, R. Figlin, Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies Journal of Clinical Oncology. ,vol. 23, pp. 3059- 3059 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3059

C. L. Sawyers, N. P. Shah, H. M. Kantarjian, J. Cortes, R. Paquette, J. Nicoll, S. A. Bai, E. Clark, A. P. Decillis, M. Talpaz, A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): Results from CA180002 Journal of Clinical Oncology. ,vol. 23, pp. 6520- 6520 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.6520